MDxHealth (NASDAQ:MDXH) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS

MDxHealth (NASDAQ:MDXH - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.07, Zacks reports. The company had revenue of $24.74 million for the quarter, compared to analyst estimates of $22.67 million. MDxHealth had a negative return on equity of 1,077.84% and a negative net margin of 49.52%.

MDxHealth Stock Performance

Shares of MDXH traded down $0.04 during mid-day trading on Friday, hitting $1.82. 77,918 shares of the company's stock were exchanged, compared to its average volume of 102,936. The company has a quick ratio of 1.45, a current ratio of 1.54 and a debt-to-equity ratio of 3.14. MDxHealth has a 52 week low of $1.55 and a 52 week high of $3.85. The stock's 50-day simple moving average is $2.00 and its 200-day simple moving average is $2.18. The firm has a market cap of $86.06 million, a price-to-earnings ratio of -1.20 and a beta of 1.34.

Analysts Set New Price Targets

Separately, Piper Sandler lowered their price objective on MDxHealth from $8.00 to $6.00 and set an "overweight" rating on the stock in a research report on Thursday, November 7th.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.